newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the